SM
BMRN icon

Sabby Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sabby Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-475
Closed -$4.98M – 310
2015
Q4 		$4.98M Sell
475
-2,436
-84% -$254K 0.27% 63
2015
Q3 		$30.7M Buy
2,911
+1,259
+76% +$168K 1.26% 13
2015
Q2 		$22.6M Buy
1,652
+1,143
+225% +$142K 0.82% 22
2015
Q1 		$6.34M Buy
+509
New +$53.9K 0.26% 66

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sabby Management's BMRN Position: Q4 2015 in Review

Sabby Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2015, closing a stake of 174,073 shares — an estimated $18.2M sold.

Sabby Management first reported a position in BMRN in Q4 2014 and held it in 2 quarters. The position peaked at $18.3M in Q3 2015. 388 funds tracked by Wall St. Rank hold BMRN as of Q4 2015.

  • Sabby Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Sabby Management sold 174,073 BioMarin Pharmaceuticals shares in Q4 2015, an estimated $18.2M.
  • Sabby Management first reported a position in BioMarin Pharmaceuticals in Q4 2014 and held it in 2 quarters.
  • Sabby Management's BioMarin Pharmaceuticals position peaked at $18.3M in Q3 2015.
  • 388 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2015.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.